Intercept Pharmaceuticals Inc (NASDAQ:ICPT) – Investment analysts at Leerink Swann issued their FY2019 EPS estimates for shares of Intercept Pharmaceuticals in a note issued to investors on Tuesday. Leerink Swann analyst J. Schwartz anticipates that the biopharmaceutical company will earn ($16.18) per share for the year. Leerink Swann has a “Market Perform” rating and a $110.00 price target on the stock.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings results on Thursday, February 23rd. The biopharmaceutical company reported ($4.84) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($3.74) by $1.10. Intercept Pharmaceuticals had a negative net margin of 3,287.95% and a negative return on equity of 66.97%. The business earned $13 million during the quarter, compared to analyst estimates of $8.96 million. During the same quarter last year, the company posted ($3.62) earnings per share. The company’s revenue was up 2966.7% compared to the same quarter last year.

WARNING: “Intercept Pharmaceuticals Inc to Post FY2019 Earnings of ($16.18) Per Share, Leerink Swann Forecasts (ICPT)” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/04/21/intercept-pharmaceuticals-inc-to-post-fy2019-earnings-of-16-18-per-share-leerink-swann-forecasts-icpt.html.

Earnings History and Estimates for Intercept Pharmaceuticals (NASDAQ:ICPT)

A number of other research analysts also recently issued reports on ICPT. Wedbush reissued an “outperform” rating and set a $224.00 price objective on shares of Intercept Pharmaceuticals in a research report on Friday, December 30th. Vetr raised shares of Intercept Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $169.70 price objective on the stock in a research report on Monday, January 9th. Oppenheimer Holdings Inc. set a $200.00 price objective on shares of Intercept Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, January 11th. Zacks Investment Research raised shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $128.00 price objective on the stock in a research report on Tuesday, January 17th. Finally, Needham & Company LLC downgraded shares of Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, January 20th. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $187.65.



Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) traded up 0.84% during trading on Friday, reaching $108.09. 332,171 shares of the company’s stock traded hands. Intercept Pharmaceuticals has a 52-week low of $96.63 and a 52-week high of $177.93. The company’s 50-day moving average is $116.49 and its 200 day moving average is $117.04. The company’s market cap is $2.68 billion.

Institutional investors have recently made changes to their positions in the company. Carmignac Gestion boosted its position in shares of Intercept Pharmaceuticals by 1.1% in the third quarter. Carmignac Gestion now owns 2,015,192 shares of the biopharmaceutical company’s stock worth $331,680,000 after buying an additional 21,600 shares during the last quarter. Emerald Advisers Inc. PA boosted its position in shares of Intercept Pharmaceuticals by 43.7% in the third quarter. Emerald Advisers Inc. PA now owns 76,079 shares of the biopharmaceutical company’s stock worth $12,522,000 after buying an additional 23,129 shares during the last quarter. Emerald Mutual Fund Advisers Trust boosted its position in shares of Intercept Pharmaceuticals by 52.4% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 63,233 shares of the biopharmaceutical company’s stock worth $10,408,000 after buying an additional 21,742 shares during the last quarter. Capital Fund Management S.A. boosted its position in shares of Intercept Pharmaceuticals by 15.1% in the third quarter. Capital Fund Management S.A. now owns 4,142 shares of the biopharmaceutical company’s stock worth $682,000 after buying an additional 542 shares during the last quarter. Finally, Aperio Group LLC boosted its position in shares of Intercept Pharmaceuticals by 13.6% in the third quarter. Aperio Group LLC now owns 2,194 shares of the biopharmaceutical company’s stock worth $361,000 after buying an additional 263 shares during the last quarter. Institutional investors own 82.28% of the company’s stock.

In related news, insider Lisa Bright sold 254 shares of the company’s stock in a transaction dated Monday, February 27th. The shares were sold at an average price of $119.48, for a total value of $30,347.92. Following the transaction, the insider now owns 21,695 shares in the company, valued at approximately $2,592,118.60. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CMO David Shapiro sold 558 shares of the company’s stock in a transaction dated Monday, April 10th. The stock was sold at an average price of $108.51, for a total transaction of $60,548.58. Following the completion of the transaction, the chief marketing officer now owns 45,465 shares in the company, valued at approximately $4,933,407.15. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,682 shares of company stock worth $190,137. 9.20% of the stock is currently owned by company insiders.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

5 Day Chart for NASDAQ:ICPT

Receive News & Stock Ratings for Intercept Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.